Drawing for DULYZIFT

USPTO serial 50193192

DULYZIFT

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
—
Law office
—

What this means

Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies. Wait for assignment and the first examiner action. Monitor TSDR monthly for status changes to 638 (assigned) or an office action.

Status 630: Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies.

Need help with DULYZIFT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Eric R. Moran

Eric R. Moran McDonnell Boehnen Hulbert & Berghoff LLP300 South Wacker Drive31st FloorChicago, IL 60606

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals; pharmaceutical preparations; pharmaceutical products; biologics; biosimilars; dulaglutide biosimilars; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for for glycemic control; pharmaceutical preparations for controlling blood sugar; biosimilars for glycemic control; pharmaceutical preparations, namely, GLP-1 receptor agonists for glycemic control; pharmaceutical preparations, namely, injectable dulaglutide biosimilars; pharmaceutical preparations, namely, injectable biosimilars for the treatment of diabetes; pharmaceutical preparations, namely, injectable biosimilars for glycemic control; pharmaceutical preparations, namely, injectable biosimilars for controlling blood sugar; pharmaceutical preparations, namely, injectable GLP-1 receptor agonists for glycemic control; pharmaceutical preparations, namely, injectable GLP-1 receptor agonists for controlling blood sugar; injectors sold filled with dulaglutide biosimilars; injectors sold filled with pharmaceutical preparations for the treatment of diabetes; injectors sold filled with pharmaceutical preparations for glycemic control; injectors sold filled with pharmaceutical preparations for controlling blood sugar; injectors sold filled with biosimilars for glycemic control; injectors sold filled with GLP-1 receptor agonists for glycemic control; injectors sold filled with GLP-1 receptor agonists for controlling blood sugarACTIVE—
042Providing information in the field of scientific and medical research related to pharmaceuticals; providing information in the field of scientific and medical research related to diabetes and diabetes treatments; research and development of pharmaceuticals; research and development of pharmaceuticals in the field of diabetes and diabetes treatmentsACTIVE—
044Providing medical information; providing health information; providing medical information in the field of diabetes and diabetes treatments; providing health information in the field of diabetes and diabetes treatments; medical and pharmaceutical consultation; pharmaceutical advice; providing information to patients in the field of administering medications; individual medical counseling services provided to patients; providing personal support services for families of patients with life threatening disorders, namely, health counseling servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 31, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 31, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance